Vorolanib is named as a drug or biological intervention in 4 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Hao Zeng (1), Peking University Cancer Hospital & Institute (1) and Betta Pharmaceuticals Co., Ltd. (1). Registered phases: Phase 2, Phase 3 and Phase 1. Conditions studied include Renal Cell Carcinoma (RCC); Renal Cell Carcinoma; Immunotherapy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07809802 | Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment (ClinicalTrials.gov ↗) Hepatic Impairment (HI) |
Phase 1 | Recruiting |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI (ClinicalTrials.gov ↗) Renal Cell Carcinoma (RCC) |
Phase 3 | Not yet open |
| NCT06523049 | Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy (ClinicalTrials.gov ↗) Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy |
Phase 2 | Not yet open |
| NCT07047001 | Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma (ClinicalTrials.gov ↗) Renal Cell Carcinoma (RCC), Adjuvant |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Renal Cell Carcinoma (RCC) | 2 |
| Renal Cell Carcinoma | 1 |
| Immunotherapy | 1 |
| Molecular Targeted Therapy | 1 |
| Hepatic Impairment (HI) | 1 |
| Adjuvant | 1 |
| Lead sponsor | Trials |
|---|---|
| Hao Zeng | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Betta Pharmaceuticals Co., Ltd. | 1 |
| Dong Wen | 1 |
| Register | Vorolanib trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vorolanib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vorolanib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.